Forte Biosciences reported positive phase 1b clinical trial results for FB102, an investigational therapy for vitiligo, showing significant improvement in disease severity compared to placebo. Patients treated with FB102 saw a 29.6% average improvement in facial vitiligo scores at 24 weeks, with greater improvements in those with more severe disease. The treatment was well-tolerated with mostly mild to moderate side effects. Forte plans to advance FB102 with upcoming Phase 2 trial results in celiac disease expected soon, highlighting the drug's broad potential.
Vishay Intertechnology introduced the VOMHA43A, a high-speed automotive optocoupler in a narrow 3.6 mm SOP-5 package that saves PCB space while enhancing signal quality. It offers industry-leading common mode transient immunity of 40 kV/µS and a peak...
At the NATO summit, President Trump secured $3 billion in deals for U.S. defense companies to expand production in Europe, enhancing NATO's missile and drone capabilities. Lockheed Martin will establish a Patriot missile sustainment facility and co-p...
Microsoft reported a 25% increase in carbon emissions in 2025, reaching 20 million metric tons, driven by the expansion of AI data centers. This rise challenges the company's 2030 climate goal to be carbon negative, as demand for AI infrastructure gr...
Anduril CEO Brian Schimpf said the company is not rushing to go public, warning that IPOs during hype cycles can lead to poor returns. Despite soaring demand for defense tech driven by increased military spending, Anduril and other firms face what Sc...
Concerns over insider trading risks linked to prediction markets are prompting companies like Goldman Sachs and Morgan Stanley to update or create policies restricting employee trades on these platforms. The Commodity Futures Trading Commission is ex...
